Results 121 to 130 of about 14,298 (222)

Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells [PDF]

Gamma delta T lymphocytes (γδT cells) have pleiotropic properties including innate cytotoxicity, which make them attractive effectors for cancer immunotherapy.
Fisher, JPH, Frosch, J, Flutter, BR, Wesemann, F, Rossig, C, Anderson, J, Gustafsson, K   +6 more
core  

Invitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody

, 2009
Despite aggressive multimodality therapy, most neuroblastoma-bearing patients relapse and survival rate remains poor. Exploration of alternative therapeutic modalities is needed.
Hsu, Wen Ming, Wang, Chung Hao, Peng, Ching An, Huang, Yao Jhang, Chang, Chia Wei   +4 more
core   +1 more source

A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor

Biomarker Research
Osteosarcoma is the commonest malignant bone tumour in children, with a poor prognosis due to limited treatment options. Antibody–drug conjugates (ADCs) offer targeted therapeutic potential but are limited by the low expression of specific antigens like ...
Jing Shan, Zicheng Lin, Harunor Rashid, Peng Huang, Lei Qiang, Yihao Liu, Guanlu Shen, Yuchen Li, Jiaming Cui, Zhi Su, Hanbo Wang, Bixuan Cao, Cheng Zhou, Veysel Kayser, Bo Ning   +14 more
doaj   +1 more source

GD2 Antibody [PDF]

, 2020
openaire   +1 more source

Ganglioside GD2 [PDF]

, 2020
openaire   +1 more source

Aktive Immunisierung mit GD2-Peptidmimotopen und anti-Idiotypen zur Immuntherapie beim Neuroblastom [PDF]

, 2013
Das Neuroblastom ist der häufigste solide, extrakranielle Tumor des Kindesalters. Die schlechte Prognose von Patienten mit fortgeschrittener Erkrankung macht die Entwicklung neuer Therapiemodalitäten zu einem der wichtigsten Forschungsziele auf dem ...
Bleeke, Matthias
core  

Dual targeting of PDPN and GD2 enhances CAR T cell efficacy against glioblastoma and promotes durable tumor control. [PDF]

Mol Ther Oncol
Hübner J, Nerreter T.
europepmc   +1 more source

GD2-targeted immunotherapy in pediatric bone sarcomas: a systematic review of emerging strategies and combination approaches. [PDF]

Front Immunol
Tirtei E, Poggi Longostrevi S, Bombaci S, Mercolini F, Pionelli MG, Asaftei SD, Fagioli F.   +6 more
europepmc   +1 more source

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies. [PDF]

Exp Hematol Oncol
Mai Y, Wang Z, Wang J, Song M, Xiang T, He Y, Chang AH, Zhang Y.   +7 more
europepmc   +1 more source

Perioperative myeloid cell remodeling shapes CAR-T cell efficacy in glioblastoma. [PDF]

Nat Commun
Pedard M, Castillo Cantero L, Ghasemi A, Marinari E, Mollica C, Davanture S, Pernot J, Widmer V, Merkler D, Egervari K, Schaller K, Bijlenga P, Bartoli A, Momjian S, Pittet MJ, Dutoit V, Migliorini D.   +16 more
europepmc   +1 more source